CNTB Stock Forecast 2025-2026
Distance to CNTB Price Targets
CNTB Price Momentum
🤔 Considering Connect Biopharma (CNTB)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest CNTB Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, CNTB has a bullish consensus with a median price target of $7.00 (ranging from $6.00 to $8.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $0.86, the median forecast implies a 717.7% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Emily Bodnar at HC Wainwright & Co., projecting a 834.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CNTB Analyst Ratings
CNTB Price Target Range
Latest CNTB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CNTB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 6, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $8.00 |
| Jun 13, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $8.00 |
| Apr 17, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $8.00 |
| Mar 4, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Initiates | $7.00 |
| Sep 13, 2023 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $5.00 |
| Feb 8, 2023 | SVB Leerink | Thomas Smith | Outperform | Maintains | $7.00 |
| Jun 2, 2022 | Cantor Fitzgerald | Louise Chen | Overweight | Initiates | $5.00 |
| May 5, 2022 | Piper Sandler | Joseph Catanzaro | Neutral | Downgrade | $1.50 |
| May 4, 2022 | SVB Leerink | Thomas Smith | Outperform | Maintains | $9.00 |
| Jan 6, 2022 | SVB Leerink | Thomas Smith | Outperform | Maintains | $22.00 |
| Jul 2, 2021 | CICC | Outperform | Initiates | $0.00 | |
| Apr 13, 2021 | Jefferies | Buy | Initiates | $0.00 | |
| Apr 13, 2021 | SVB Leerink | Outperform | Initiates | $0.00 |
Connect Biopharma Holdings Ltd. (CNTB) Competitors
The following stocks are similar to Connect Biopharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Connect Biopharma Holdings Ltd. (CNTB) Financial Data
Connect Biopharma Holdings Ltd. has a market capitalization of $47.30M with a P/E ratio of 0.0x. The company generates $24.12M in trailing twelve-month revenue with a -88.7% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of +24.6% and return on equity of -17.9%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Connect Biopharma Holdings Ltd. (CNTB) Business Model
About Connect Biopharma Holdings Ltd.
Develops therapies for inflammatory diseases.
Connect Biopharma Holdings Ltd. generates revenue by developing and commercializing innovative biopharmaceutical therapies targeting inflammatory diseases. The company utilizes its proprietary T cell modulation technology to create a pipeline of clinical-stage treatments, focusing on conditions such as asthma, psoriasis, and inflammatory bowel disease. By engaging in research collaborations and partnerships, it enhances its research and development capabilities, potentially leading to successful product launches and market penetration.
Based in China, Connect Biopharma operates within the global pharmaceutical market, emphasizing its role in delivering novel biologic treatments. The company is committed to addressing unmet medical needs and adapting advancements in biotechnology to provide effective solutions for healthcare providers and patients.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
81
CEO
Dr. Barry D. Quart Pharm.D.
Country
United States
IPO Year
2020
Website
www.connectbiopharm.comConnect Biopharma Holdings Ltd. (CNTB) Latest News & Analysis
Connect Biopharma Holdings (Nasdaq: CNTB) will participate in the Leerink Partners Global Biopharma Conference on March 12, 2025, at 1:40 p.m. ET. A webcast will be available.
Management participation in key conferences can signal investor confidence and provide updates on product development, influencing stock sentiment and potential investment decisions.
Steven Chan has been appointed as the Chief Financial Officer of Attovia, bringing his expertise in finance leadership to the company.
Steven Chan's appointment as CFO could signal a strategic shift or focus on financial stability at Attovia, potentially impacting investor confidence and company performance.
CNTB Stock Dips Amid Biotech Sector Volatility
5 months agoCone Biopharma (CNTB) shares fell 5.47% to $1.21, with a trading volume of 777 shares and no significant turnover rate reported.
Cone Biopharma's 5.47% stock drop signals potential concerns about its performance or market confidence, impacting investor sentiment and liquidity. Low trading volume indicates limited interest.
Concordia Biotech (CNTB) stock rose 5.48% to $1.49 per share, with a trading volume of 16,435 shares and a turnover rate of 0.03%.
Concordia Biotech's 5.48% stock price increase signals positive market sentiment, potentially attracting more investors and indicating growing interest in the company's performance.
Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
6 months agoConnect Biopharma Holdings Limited reported its financial results for H1 2024, focusing on its clinical-stage biopharmaceutical efforts for inflammatory diseases.
Connect Biopharma's financial results and business update signal its progress in clinical development, impacting investor sentiment and potential stock performance in the biopharmaceutical sector.
Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
8 months agoConnect Biopharma Holdings Limited will participate in one-on-one investor meetings at the Leerink Partners Inflammation and Immunology Forum on July 9-10, 2024, in Boston.
Connect Biopharma's leadership engaging directly with investors at a key forum signals potential developments in chronic inflammatory disease treatments, influencing investor sentiment and stock performance.
Frequently Asked Questions About CNTB Stock
What is Connect Biopharma Holdings Ltd.'s (CNTB) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Connect Biopharma Holdings Ltd. (CNTB) has a median price target of $7.00. The highest price target is $8.00 and the lowest is $6.00.
Is CNTB stock a good investment in 2025?
According to current analyst ratings, CNTB has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.86. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CNTB stock?
Wall Street analysts predict CNTB stock could reach $7.00 in the next 12 months. This represents a 717.7% increase from the current price of $0.86. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Connect Biopharma Holdings Ltd.'s business model?
Connect Biopharma Holdings Ltd. generates revenue by developing and commercializing innovative biopharmaceutical therapies targeting inflammatory diseases. The company utilizes its proprietary T cell modulation technology to create a pipeline of clinical-stage treatments, focusing on conditions such as asthma, psoriasis, and inflammatory bowel disease. By engaging in research collaborations and partnerships, it enhances its research and development capabilities, potentially leading to successful product launches and market penetration.
What is the highest forecasted price for CNTB Connect Biopharma Holdings Ltd.?
The highest price target for CNTB is $8.00 from Emily Bodnar at HC Wainwright & Co., which represents a 834.5% increase from the current price of $0.86.
What is the lowest forecasted price for CNTB Connect Biopharma Holdings Ltd.?
The lowest price target for CNTB is $6.00 from at , which represents a 600.9% increase from the current price of $0.86.
What is the overall CNTB consensus from analysts for Connect Biopharma Holdings Ltd.?
The overall analyst consensus for CNTB is bullish. Out of 5 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are CNTB stock price projections?
Stock price projections, including those for Connect Biopharma Holdings Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
